Santen Pharmaceutical Co., Ltd. (TYO:4536)
1,915.50
+27.00 (1.43%)
May 29, 2026, 3:30 PM JST
Santen Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 80,875 | 92,997 | 94,582 | 57,903 | 83,014 |
Cash & Short-Term Investments | 80,875 | 92,997 | 94,582 | 57,903 | 83,014 |
Cash Growth | -13.04% | -1.68% | 63.35% | -30.25% | 32.00% |
Accounts Receivable | 71,754 | 71,759 | 90,539 | 107,165 | 99,591 |
Other Receivables | 76 | 324 | - | 60 | - |
Receivables | 71,830 | 72,083 | 90,539 | 107,225 | 99,591 |
Inventory | 64,584 | 51,590 | 43,185 | 39,352 | 37,141 |
Other Current Assets | 11,469 | 7,630 | 7,833 | 8,846 | 9,680 |
Total Current Assets | 228,758 | 224,300 | 236,139 | 213,326 | 229,426 |
Property, Plant & Equipment | 78,115 | 72,954 | 71,576 | 66,173 | 56,287 |
Long-Term Investments | 33,658 | 26,539 | 33,400 | 42,560 | 40,944 |
Goodwill | - | 8,242 | 8,303 | 7,385 | 13,715 |
Other Intangible Assets | 71,658 | 67,225 | 75,516 | 88,924 | 116,502 |
Long-Term Deferred Tax Assets | 10,843 | 10,017 | 10,765 | 2,810 | 3,103 |
Other Long-Term Assets | 1 | - | - | 1 | -1 |
Total Assets | 423,033 | 409,277 | 435,699 | 421,179 | 459,976 |
Accounts Payable | 35,350 | 38,989 | 43,531 | 44,945 | 41,185 |
Accrued Expenses | - | 6,514 | 7,792 | - | - |
Short-Term Debt | - | 274 | 54 | 245 | 10,936 |
Current Portion of Leases | - | 3,015 | 2,694 | 2,811 | 3,029 |
Current Income Taxes Payable | 4,535 | 3,029 | 5,710 | 6,745 | 4,198 |
Other Current Liabilities | 47,983 | 35,016 | 33,015 | 34,758 | 36,473 |
Total Current Liabilities | 87,868 | 86,837 | 92,796 | 89,504 | 95,821 |
Long-Term Debt | - | 26,483 | 26,915 | 28,198 | 12,677 |
Long-Term Leases | - | 4,457 | 4,947 | 4,953 | 6,290 |
Pension & Post-Retirement Benefits | 1,424 | 1,221 | 1,292 | 1,271 | 1,077 |
Long-Term Deferred Tax Liabilities | 4,338 | 2,606 | 1,377 | 1,592 | 2,526 |
Other Long-Term Liabilities | 33,386 | 2,492 | 3,002 | 2,365 | 4,742 |
Total Liabilities | 127,016 | 124,096 | 130,329 | 127,883 | 123,133 |
Common Stock | 8,824 | 8,806 | 8,777 | 8,702 | 8,672 |
Additional Paid-In Capital | 9,595 | 9,797 | 9,854 | 9,789 | 9,370 |
Retained Earnings | 223,285 | 228,291 | 240,029 | 238,071 | 290,477 |
Treasury Stock | -979 | -1,161 | -1,018 | -364 | -718 |
Comprehensive Income & Other | 56,264 | 40,509 | 48,413 | 37,781 | 29,687 |
Total Common Equity | 296,989 | 286,242 | 306,055 | 293,979 | 337,488 |
Minority Interest | -972 | -1,061 | -685 | -683 | -645 |
Shareholders' Equity | 296,017 | 285,181 | 305,370 | 293,296 | 336,843 |
Total Liabilities & Equity | 423,033 | 409,277 | 435,699 | 421,179 | 459,976 |
Total Debt | - | 34,229 | 34,610 | 36,207 | 32,932 |
Net Cash (Debt) | 80,875 | 58,768 | 59,972 | 21,696 | 50,082 |
Net Cash Growth | 37.62% | -2.01% | 176.42% | -56.68% | -5.04% |
Net Cash Per Share | 246.29 | 168.06 | 162.91 | 56.00 | 125.06 |
Filing Date Shares Outstanding | 321.61 | 337.56 | 356.09 | 369.88 | 393.3 |
Total Common Shares Outstanding | 321.61 | 341.36 | 363.21 | 375.54 | 400.27 |
Working Capital | 140,890 | 137,463 | 143,343 | 123,822 | 133,605 |
Book Value Per Share | 923.45 | 838.52 | 842.64 | 782.82 | 843.15 |
Tangible Book Value | 225,331 | 210,775 | 222,236 | 197,670 | 207,271 |
Tangible Book Value Per Share | 700.64 | 617.45 | 611.87 | 526.36 | 517.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.